GH-pathway / body-composition support
A two-pathway GH stack for visceral-fat support, body composition, recovery, and metabolic-health goals.
The Science
Tesamorelin + Ipamorelin combines two complementary GH-pathway mechanisms.
Tesamorelin is a GHRH analog that stimulates pituitary growth-hormone release through GHRH receptor activation. It is best known for its role in visceral-fat reduction and metabolic-health support when medically appropriate.
Ipamorelin is a selective ghrelin mimetic that amplifies growth-hormone secretion through ghrelin-receptor activation without broadly elevating cortisol or prolactin.
Together, Tesamorelin and Ipamorelin support endogenous GH pulsatility through two distinct but complementary pathways. Tesamorelin supports the GHRH pathway, while Ipamorelin supports GH pulse amplification through ghrelin-receptor signaling.
This two-pathway approach supports body-composition goals through GH-mediated lipolysis, visceral-fat support, lean-tissue preservation, recovery capacity, sleep-quality support, and metabolic-health planning.
Core Components
Tesamorelin activates the GHRH pathway, stimulating natural pituitary growth-hormone release in a pulsatile pattern. It is best known for its role in visceral adipose tissue reduction and metabolic-health support when medically appropriate.
Ipamorelin activates ghrelin-receptor signaling to amplify growth-hormone secretion. It is valued for its selective GH-secretagogue profile without the broader cortisol or prolactin stimulation associated with some older secretagogues.
Tesamorelin supports the GHRH pathway, while Ipamorelin supports the ghrelin-receptor pathway. Together, they provide complementary GH-pathway signaling for visceral-fat support, body composition, recovery capacity, metabolic health, and healthy-aging goals.
How It Works
Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, triggering endogenous growth-hormone release in a natural pulsatile pattern. It is best known for its role in visceral adipose tissue reduction through GH-mediated lipolysis and metabolic support.
Ipamorelin selectively activates ghrelin receptors to amplify growth-hormone secretion without broadly elevating cortisol or prolactin. This provides clean, pulsatile GH release that complements Tesamorelin’s GHRH-pathway action.
Tesamorelin supports the GHRH pathway. Ipamorelin strengthens the GH pulse through ghrelin-receptor signaling. Together, they create a complementary GH-pathway strategy for visceral-fat support, body composition, recovery capacity, sleep quality, and metabolic-health planning.
Primary Benefits
Tesamorelin’s GHRH-pathway activity is best known for targeting visceral adipose tissue, while the GH cascade supports lipolysis and improved body-composition metrics.
Dual GH-pathway activation through GHRH and ghrelin receptors supports robust, pulsatile growth-hormone release that follows a more natural physiologic pattern.
Tesamorelin and Ipamorelin support metabolic-health goals through GH-pathway signaling, visceral-fat support, body-composition change, glucose-metabolism considerations, and recovery-driven metabolic resilience.
Growth-hormone signaling supports tissue repair, training recovery, connective-tissue resilience, and adaptation after exercise or physical stress.
GH-pathway signaling supports protein balance, lean-tissue preservation, and preferential fat-utilization pathways during body-composition programs.
Tesamorelin supports the GHRH pathway, while Ipamorelin amplifies GH pulse strength through ghrelin-receptor signaling. Together, they provide a two-pathway GH strategy for visceral-fat support, recovery, body composition, metabolic health, and healthy-aging goals.
Safety / Clinical Positioning
Tesamorelin + Ipamorelin combines two complementary GH-pathway mechanisms. Tesamorelin is a GHRH analog with an FDA-approved use in a specific HIV-associated lipodystrophy context, while Ipamorelin is a selective GH secretagogue studied for pituitary growth-hormone release.
Why IPS is different
Many consumers encounter products online labeled for research use only, not for human consumption, or laboratory chemicals. Those labels matter because they are not intended for patient care.
A product mixed at home from an online powder and labeled research use only is fundamentally different from care that begins with consultation, provider review, appropriate prescribing, and ongoing clinical guidance.
Annual Membership
12-month IPS members receive access to preferred pricing on eligible peptide programs after consultation and medical review.
Contact
Send your details and IPS can follow up about consultation scheduling and next steps.